15.3
Share of global GDP in manufacturing in 2023
Source: World Bank Group
Danish pharmaceutical company Novo Nordisk recently announced plans to spend approximately $1.2 billion to build a new production facility in Odense, Denmark. The scope of the project includes a finished production plant and a warehouse with a total of more than 430,000 square meters.
The main facility is expected to include on-site solar power generation. The owner intends to plant more than 4,000 trees there.
The manufacturing site is designed for modularity and flexibility, so it can accommodate the production of drugs for multiple rare diseases such as hemophilia, according to Novo Nordisk.
The facility will use “advanced technology and innovative equipment to ensure the highest quality for patients and meet the growing global demand for our life-changing medicines,” said Henrik Wulff, Novo’s executive vice president of product supply, quality and IT Nordisk, in a statement.
Work is already underway, although a Novo Nordisk representative declined to name the contractors working on the project. It is scheduled to end in 2027.
The drugmaker has a separate project in North Carolina to expand production of its popular weight loss and diabetes treatments Wegovy and Ozempic.
Morrisville, North Carolina-based BE&K is the construction manager for this $4.1 billion project.
The American project has some similarities to the recently announced work in Denmark, such as the inclusion of on-site solar. Novo Nordisk has said it aims to achieve LEED Gold certification for the facility. Completion of this plant is planned in phases, starting in 2027 and continuing until 2029.
